Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.42 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ICOSLG | O75144 | 1/20 | 0.42 |
| ▸ | ICOS | Q9Y6W8 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022705 | 0.85 | PDE4D (0.58) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5022500 | 0.79 | TUBB4A (0.47) | KMT2AMAPTPOLBTDP1TUBB4A | |
| SCHEMBL4698806 | 0.76 | PDE4A (0.69) | NPC1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL5022909 | 0.74 | KMT2A (0.55) | NPC1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL5546551 | 0.73 | MAPT (0.48) | NPC1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL5022663 | 0.73 | PDE4D (0.60) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5016457 | 0.72 | NR4A2 (0.49) | NPC1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL5022711 | 0.72 | MAPT (0.46) | NPC1RAB9AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL5018042 | 0.68 | KMT2A (0.43) | NPC1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5016441 | 0.67 | PDE4A (0.57) | NPC1RAB9AKMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LTC4S, TSLP, GPR119 | NPC1 853/4885RAB9A 3448/4885KMT2A 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.